Jane Street
VOR icon

Jane Street’s Vor Biopharma VOR Stock Holding History

Jane Street’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,225
Closed -$173K – 13112
2025
Q4 		$173K Sell
13,225
-8,095
-38% -$151K ﹤0.01% 9843
2025
Q3 		$1.04M Sell
21,320
-8,190
-28% -$329K ﹤0.01% 6238
2025
Q2 		$956K Buy
+29,510
New +$261K ﹤0.01% 5701

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's VOR Position: Q1 2026 in Review

Jane Street reduced its Vor Biopharma (VOR) stake by 17% in Q1 2026, selling an estimated $225K and leaving 75,890 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #5841.

Jane Street first reported a position in VOR in Q3 2022 and has held it in 13 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Jane Street held 75,890 shares of Vor Biopharma worth $1.35M as of Q1 2026.
  • Jane Street sold 15,920 Vor Biopharma shares in Q1 2026, an estimated $225K.
  • Vor Biopharma made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5841 holding.
  • Jane Street first reported a position in Vor Biopharma in Q3 2022 and has held it in 13 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.